{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T02:14:26Z","timestamp":1758593666276,"version":"3.44.0"},"reference-count":122,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/P027938\/1"],"award-info":[{"award-number":["MR\/P027938\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["134293"],"award-info":[{"award-number":["134293"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Our objective was to evaluate whether antihypertensives affect fetal (FHR) or neonatal (neoHR) heart rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>Electronic databases and clinical trial registers were searched to August 31, 2024. Eligibility included randomized (RCTs) or observational studies evaluating antihypertensives for pregnancy hypertension. Two reviewers independently assessed studies for inclusion and extracted data. Random effects meta\u2010analysis was used to determine risk ratios (RRs) and 95% confidence intervals (CIs). Network meta\u2010analysis was undertaken in a sensitivity analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010four RCTs (<jats:italic>n<\/jats:italic> =\u20095736 pregnancies) and 28 observational studies (<jats:italic>n<\/jats:italic> =\u20092\u2009283\u2009855) reported FHR (usually visually\u2010interpreted) or neoHR (usually clinically\u2010assessed).<\/jats:p><\/jats:sec><jats:sec><jats:title>FHR: Non\u2010Severe Hypertension<\/jats:title><jats:p>Antihypertensives did not increase adverse FHR effects in RCTs of antihypertensives versus placebo\/no therapy (RR\u2009=\u20091.08, 95% CI [0.62\u20131.89]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200943%; <jats:italic>N<\/jats:italic> =\u200910, <jats:italic>n<\/jats:italic> =\u20091567 pregnancies), antihypertensives versus methyldopa (RR\u2009=\u20091.40 [0.97\u20132.04]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u20090%; <jats:italic>N<\/jats:italic> =\u20096, <jats:italic>n<\/jats:italic> =\u2009515), or labetalol or pure beta\u2010blockers versus other antihypertensives (RR\u2009=\u20091.70 [0.96\u20132.99]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200930%; <jats:italic>N<\/jats:italic> =\u20095, <jats:italic>n<\/jats:italic> =\u2009501). In observational studies, adverse FHR effects were more common with: labetalol versus methyldopa, nifedipine or Chinese herbal medication (RR\u2009=\u20092.17 [1.15\u20134.08]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200947%; <jats:italic>N<\/jats:italic> =\u20094, <jats:italic>n<\/jats:italic> =\u2009664), and bendroflumethiazide versus metoprolol (but not hydralazine), but 95% CIs were wide.<\/jats:p><\/jats:sec><jats:sec><jats:title>FHR: Severe Hypertension<\/jats:title><jats:p>Antihypertensives had no FHR effects in RCTs of antihypertensives versus either: placebo\/no therapy (RR\u2009=\u20090.43 [0.16\u20131.20]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u20090%; <jats:italic>N<\/jats:italic> =\u20093, <jats:italic>n<\/jats:italic> =\u2009242), hydralazine (RR\u2009=\u20090.71 [0.29\u20131.72]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200913%; <jats:italic>N<\/jats:italic> =\u200911, <jats:italic>n<\/jats:italic> =\u2009727), or CCBs (RR\u2009=\u20090.52 [0.12\u20132.16]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u20090%, <jats:italic>N<\/jats:italic> =\u20099, <jats:italic>n<\/jats:italic> =\u20091675). In observational studies, there was no difference for labetalol versus other antihypertensives (RR\u2009=\u20090.34 [0.10\u20131.14], <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200987%; <jats:italic>N<\/jats:italic> =\u20094, <jats:italic>n<\/jats:italic> =\u2009590), with heterogeneity due to a lower\u2010quality labetalol versus hydralazine study. There were fewer adverse FHR effects for nifedipine versus hydralazine study (RR\u2009=\u20090.09 [0.01\u20130.68]; <jats:italic>n<\/jats:italic> =\u200949).<\/jats:p><\/jats:sec><jats:sec><jats:title>NeoHR: Severe Hypertension<\/jats:title><jats:p>RCTs of antihypertensives versus placebo\/no therapy were not associated with adverse neoHR effects (RR\u2009=\u20091.26 [0.31\u20135.19]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200966%; <jats:italic>N<\/jats:italic> =\u20094, <jats:italic>n<\/jats:italic> =\u2009406), with heterogeneity attributed to more neoHR effects with continuously monitored neoHR. Observational studies revealed no effect on neoHR of antihypertensives versus no therapy (RR\u2009=\u20091.06 [0.67\u20131.67]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u200954%; <jats:italic>N<\/jats:italic> =\u20094, <jats:italic>n<\/jats:italic> =\u200937\u2009359), but labetalol was associated with more adverse effects and metoprolol with fewer. In RCTs of antihypertensives versus other antihypertensives, there was no difference in adverse neoHR (RR\u2009=\u20093.0 [0.13\u201371.74]; <jats:italic>N<\/jats:italic> =\u20093, <jats:italic>n<\/jats:italic> =\u2009162). Observational studies showed adverse neoHR effects in labetalol versus pure beta\u2010blockers (RR\u2009=\u20091.99 [1.36\u20132.91]; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u20090%; <jats:italic>N<\/jats:italic> =\u20093, <jats:italic>n<\/jats:italic> =\u200916\u2009204). No severe hypertension RCTs reported neoHR. Observational studies were limited. Network meta\u2010analysis showed no significant relationships between antihypertensives and FHR or neoHR; 95% CIs were very wide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Evidence is inadequate to draw reliable conclusions about the impact of antihypertensives on FHR or neoHR. At present, adverse FHR or neoHR effects should be attributed to evolving placental dysfunction.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.70019","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:37:08Z","timestamp":1755751028000},"page":"1822-1837","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antihypertensive therapy for pregnancy hypertension and implications for fetal and neonatal heart rate monitoring: A\u00a0systematic review of randomized trials and observational studies"],"prefix":"10.1111","volume":"104","author":[{"given":"Akalya","family":"Ganeshamoorthy","sequence":"first","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-4714","authenticated-orcid":false,"given":"Omiete Fubara","family":"Duke","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2564-7348","authenticated-orcid":false,"given":"Hiten D.","family":"Mistry","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-1677","authenticated-orcid":false,"given":"Jeffrey N.","family":"Bone","sequence":"additional","affiliation":[{"name":"Clinical Research Support Unit British Columbia Children's Hospital Research Institute  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Vidler","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-429X","authenticated-orcid":false,"given":"Edgardo","family":"Abalos","sequence":"additional","affiliation":[{"name":"Department of Obstetrics Maternity Mart\u00edn Hospital  Rosario Santa Fe Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Badawy","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Medicine King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-7670","authenticated-orcid":false,"given":"Asma","family":"Khalil","sequence":"additional","affiliation":[{"name":"Molecular &amp; Clinical Sciences Research Institute St. George's, University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"von Dadelszen","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-610X","authenticated-orcid":false,"given":"Laura A.","family":"Magee","sequence":"additional","affiliation":[{"name":"Department of Women and Children's Health King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2109523"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17370"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2021.09.008"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404595"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201295"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.08.018"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03382-3"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(00)70508-4"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)39495-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409157128"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(87)80104-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1081\/PRG-120028291"},{"key":"e_1_2_11_14_1","unstructured":"King's College Hospital L.Full Day Cardiotogography Masterclass.2024."},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","year":"2022","author":"Higgins JPT","key":"e_1_2_11_15_1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18415"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13649"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16319"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"volume-title":"Identifying and handling potentially untrustworthy trials \u2013 trustworthiness screening tool (TST) developed by the Cochrane pregnancy and childbirth group","year":"2023","author":"Alfirevic ZKF","key":"e_1_2_11_20_1"},{"key":"e_1_2_11_21_1","unstructured":"WellsGA SheaB O'ConnellD et\u00a0al.The Newcastle\u2010Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta\u2010Analyses.2000."},{"key":"e_1_2_11_22_1","unstructured":"Joanna Briggs Institute.Checklist for Case Reports 2017.https:\/\/jbi.global\/sites\/default\/files\/2019\u201005\/JBI_Critical_Appraisal\u2010Checklist_for_Case_Reports2017_0.pdf"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1167"},{"key":"e_1_2_11_25_1","unstructured":"vanValkenhoefG KuiperJ.Network Meta\u2010Analysis Using Bayesian Methods. R package version 1.0\u201322\u2009023.https:\/\/CRAN.R\u2010project.org\/package=gemtc"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90357-7"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(87)90181-0"},{"volume-title":"Labetalol in Pregnancy\u2010Induced Hypertension: Fetal and Maternal Effects","year":"1982","author":"Walker J","key":"e_1_2_11_28_1"},{"issue":"2","key":"e_1_2_11_29_1","first-page":"168","article-title":"Randomized trial of atenolol and methyldopa in pregnancy related hypertension","volume":"3","author":"Thorley KJ","year":"1984","journal-title":"Clinical and Experimental Hypertension Part B\u2010Hypertension in Pregnancy"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(12)80005-6"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)91297-P"},{"issue":"3","key":"e_1_2_11_32_1","first-page":"323","article-title":"A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term","volume":"70","author":"Sibai BM","year":"1987","journal-title":"Obstet Gynecol"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198300252-00061"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(86)90066-3"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1988.tb06571.x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1989.tb01574.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1991.tb121126.x"},{"issue":"1","key":"e_1_2_11_38_1","first-page":"39","article-title":"A comparative evaluation of metoprolol and methyldopa in the management of pregnancy induced hypertension","volume":"44","author":"Oumachigui A","year":"1992","journal-title":"Indian Heart J"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpme.1996.24.2.177"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6832.946"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641958309006092"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7951342"},{"key":"e_1_2_11_43_1","first-page":"137","article-title":"Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol","volume":"81","author":"Lardoux H","year":"1988","journal-title":"Arch Mal Coeur Vaiss"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641968009037147"},{"issue":"3","key":"e_1_2_11_45_1","first-page":"354","article-title":"Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial","volume":"84","author":"Jannet D","year":"1994","journal-title":"Obstet Gynecol"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6382.1927"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348509156729"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(86)90015-9"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPM.2008.060"},{"issue":"1","key":"e_1_2_11_50_1","first-page":"2023","article-title":"Management of Pregnancy induced hypertension (PIH) by methyldopa versus labetalol\u2010A randomized controlled trial","volume":"10","author":"Digra M","year":"2023","journal-title":"Eur J Mol Clin Med"},{"issue":"4","key":"e_1_2_11_51_1","first-page":"489","article-title":"Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension","volume":"53","author":"Arias F","year":"1979","journal-title":"Obstet Gynecol"},{"issue":"4","key":"e_1_2_11_52_1","first-page":"274","article-title":"A randomized, double\u2010blind, comparative trial of nifedipine and methyldopa in moderate pregnancy induced hypertension","volume":"5","author":"Aparna J","year":"2013","journal-title":"Pharm Lett"},{"key":"e_1_2_11_53_1","first-page":"201","article-title":"A comparative randomised controlled parallel group study of maternal, fetal and neonatal outcomes of labetalol versus methyldopa in the treatment of new onset hypertension during pregnancy","volume":"3","author":"Verma R","year":"2012","journal-title":"Int J Pharm Bio Sci"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(88)80027-9"},{"key":"e_1_2_11_55_1","first-page":"72","article-title":"Efficacy of labetalol combined with magnesium sulfate in the treatment of hypertension during pregnancy and its effects on serum PAPPA and PLGF levels","volume":"86","author":"Wu J","year":"2024","journal-title":"Indian J Pharm Sci"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3135043"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-011-2205-2"},{"issue":"1","key":"e_1_2_11_58_1","first-page":"37","article-title":"Uterine and Fetal Flow Velocity Wake\u2010Forms in Hypertensive Preganancy\u2010 the Effect of a Single Dose of Nifedipine","volume":"76","author":"Pirhonen JP","year":"1990","journal-title":"Obstet Gynecol"},{"issue":"4","key":"e_1_2_11_59_1","first-page":"192","article-title":"The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancies complicated by hypertension","volume":"79","author":"Puzey MS","year":"1991","journal-title":"S Afr Med J"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000445283"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2016.1193145"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2013.766695"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(95)02351-C"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-012-2371-x"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6299.1077"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2005.01.024"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0731"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2022.43"},{"issue":"12","key":"e_1_2_11_69_1","first-page":"1507","article-title":"Effects of maternal labetalol on the newborn infant","volume":"29","author":"Munshi UK","year":"1992","journal-title":"Indian Pediatr"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00608227"},{"issue":"7","key":"e_1_2_11_71_1","first-page":"487","article-title":"A comparison of acebutolol with methyldopa in hypertensive pregnancy","volume":"3","author":"Williams E","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1980.tb04618.x"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641958209037186"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(12)90905-9"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12439"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70315-7"},{"issue":"4","key":"e_1_2_11_77_1","first-page":"328","article-title":"Comparison of oral nifedipine with intravenous hydralazine for acute hypertensive emergencies of pregnancy","volume":"30","author":"Sabir S","year":"2016","journal-title":"J Postgraduate Med Inst"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2011.03151.x"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2022.05.001"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641959209031031"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641959709069085"},{"issue":"3","key":"e_1_2_11_82_1","first-page":"328","article-title":"A Comparative Trial of Labetalol and Hydralazine in the Acute Management of Severe Hypertension Complicating Pregnancy","volume":"70","author":"Mabie WC","year":"1987","journal-title":"Obstet Gynecol"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.332.12243"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(93)90770-W"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641958209139860"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2018.02.011"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-002-1406-3"},{"issue":"7","key":"e_1_2_11_88_1","article-title":"Comparing intravenous labetalol and intravenous hydralazine for managing severe gestational hypertension","volume":"15","author":"Ehikioya E","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31282-6"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.1992.tb02846.x"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.125944.1"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19751"},{"issue":"8","key":"e_1_2_11_93_1","first-page":"610","article-title":"A comparison of Oral Nifedipine and intravenous labetalol for severe pregnancy induced hypertension","volume":"14","author":"Baske S","year":"2022","journal-title":"Int J Pharm Pharm Sci"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2010.10.006"},{"issue":"6","key":"e_1_2_11_95_1","first-page":"354","article-title":"Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy","volume":"71","author":"Ashe RG","year":"1987","journal-title":"S Afr Med J"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2002.810105.x"},{"issue":"6","key":"e_1_2_11_97_1","first-page":"517","article-title":"A randomized trial of intravenous labetalol versus Oral Nifedipine in acute blood pressure control in hypertensive emergencies of pregnancy","volume":"14","author":"Anilasree A","year":"2023","journal-title":"Res J Pharm, Biol Chem Sci"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12554"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1685"},{"issue":"3","key":"e_1_2_11_100_1","first-page":"331","article-title":"Nifedipine in the Treatment of Severe Preeclampsia","volume":"77","author":"Fenakel K","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000188729.73807.16"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2011.12.012"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpme.1993.21.1.69"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1988.tb06818.x"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-999503"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.08.018"},{"key":"e_1_2_11_107_1","first-page":"34","article-title":"Comparison between adverse effects of I\/v Inj labetalol vs Inj hydralazine during treatment of hypertension in pregnancy","volume":"17","author":"Yousaf MK","year":"2023","journal-title":"Lahore Medical and Dental College"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2016.50"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxz134"},{"journal-title":"Paediatr Child Health","article-title":"Identification and management of neonatal hypoglycaemia in the full term infant (2017). A BAPM framework for practice","author":"British Association of Perinatal Medicine","key":"e_1_2_11_110_1"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19159616"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2006.02.015"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641959209031044"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1986.tb07950.x"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002256"},{"issue":"11","key":"e_1_2_11_116_1","first-page":"724","article-title":"Short\u2010term neonatal outcome among term infants after in\u2010utero exposure to Beta blockers","volume":"21","author":"Mazkereth R","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.59.11.1061"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.09.009"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(95)80020-S"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(11)90801-1"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(89)90476-6"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)10812-4"},{"issue":"10","key":"e_1_2_11_123_1","article-title":"Antihypertensive drug therapy for mild to moderate hypertension during pregnancy","volume":"10","author":"Abalos E","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.70019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:31:54Z","timestamp":1758526314000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.70019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/aogs.70019"],"URL":"https:\/\/doi.org\/10.1111\/aogs.70019","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"type":"print","value":"0001-6349"},{"type":"electronic","value":"1600-0412"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}